CORESTEM
Corestem is an innovative company that integrates scientific expertise, creativity, and cutting-edge technology, and is opening a new era of personalized medical care.
CORESTEM
Industry:
Biopharma Pharmaceutical Therapeutics
Founded:
2003-01-01
Address:
Seongnam, Kyonggi-do, South Korea
Country:
South Korea
Website Url:
http://www.corestem.com
Total Employee:
1+
Status:
Active
Contact:
+82 2-497-3711
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Analytics Google Tag Manager Google Universal Analytics Apache Global Site Tag Mobile Non Scaleable Content AJAX Libraries API
Similar Organizations
Ichorion Therapeutics
Ichorion Therapeutics is a biopharmaceutical company that develop treatments for rare diseases with unmet medical needs.
Lasting Effect Pharma
Lasting Effect is an Israeli pharma startup. R&D Company dedicated to research, formulation, patenting the implementation of its technology.
Vion Pharmaceuticals Inc
Vion Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes cancer treatment technologies.
Stock Details
Official Site Inspections
http://www.corestem.com Semrush global rank: 6.89 M Semrush visits lastest month: 714
- Host name: 183.111.169.45
- IP address: 183.111.169.45
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "CoreStem"
First licensed stem cell therapy for ALS
CORESTEM is a biotechnology company specializing in the research and development of personalized stem cell therapies for neurological and autoimmune diseases. Its lead product is …See details»
corestemchemon Stemcell Celltherapy
CorestemChemon's biopharmaceutical division aims to develop new drugs based on stem cell therapy technology. They are currently conducting clinical trials targeting neurodegenerative …See details»
CoreStem - Crunchbase Company Profile & Funding
Corestem is a biopharmaceutical company that researches and commercializes stem cell technology. Corestem is an innovative company that integrates scientific expertise, creativity, and cutting-edge technology, and is opening a new era of …See details»
Company CORESTEMCHEMON Inc. - MarketScreener.com
Corestemchemon Inc, formerly Corestem Inc, is a Korea-based company engaged in the development, production and sale of stem cell therapies for intractable diseases. The …See details»
History | COMPANY | corestemchemon Stemcell Celltherapy
Non-clinical CRO ChemOn merged and renamed to CorestemChemon. Mutual Visit Evaluation by OECD. GLP certification (MFDS) for safety pharmacology (Nav 1.5, Cav 1.2, MEA). …See details»
First licensed stem cell therapy for ALS - Nature
CORESTEM is a biotechnology company specializing in the research and development of personalized stem cell therapies for neurological and autoimmune diseases. Its lead product is NeuroNata-R...See details»
Corestemchemon Inc. Company Profile - South Korea - EMIS
Oct 31, 2024 · Corestemchemon Inc. is a company located in Seoul, South Korea. It was formed in December 2022 through the merger of Coastem, specializing in stem cell therapies, and …See details»
Efficacy and safety of Lenzumestrocel (Neuronata-R
May 18, 2022 · A single cycle (two repeated treatments) with intrathecal autologous bone marrow-derived mesenchymal stem cells (BM-MSCs, 26-day interval) showed safety and provided …See details»
Kyung Suk Kim – CEO, Corestem - PharmaBoardroom
Jun 15, 2020 · Kyung Suk Kim, CEO of Corestem, the first company to receive approval for a stem cell therapy for Amyotrophic Lateral Sclerosis (ALS) in Korea, recounts the firm’s main achievements since her previous interview with …See details»
Corestem Company Profile 2024: Stock Performance
Corestemchemon Inc is a biopharmaceutical company that researches and commercializes stem cell technology. It has developed NEURONATA-R inj., a stem cell therapy for Lou Gehrig's disease which is a rare incurable disease, …See details»
First licensed stem cell therapy for ALS - corestemchemon.com
CORESTEM is a biotechnology company specializing in the research and development of personalized stem cell therapies for neurological and autoim-mune diseases. Its lead product …See details»
Corestem Shares Protocol for Long-term NeuroNata-R Trial - ALS …
Jul 7, 2022 · Corestem is still enrolling participants in its Phase 3 clinical trial of NeuroNata-R (lenzumestrocel), a stem cell therapy that is conditionally approved to treat amyotrophic lateral …See details»
US Sites Likely for Phase 3 Trial of NeuroNata-R, ALS Stem Cell...
Mar 26, 2021 · A Phase 3 trial of NeuroNata-R, a stem cell injection therapy now enrolling adult patients in South Korea, has FDA approval to open US sites, Corestem says.See details»
Corestem - Overview, News & Similar companies | ZoomInfo.com
View Corestem (www.corestem.com) location in Seoul, South Korea , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
Korean Corestem Targets US Market for Ground-Breaking
Jun 18, 2020 · After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the US market and an …See details»
Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in …
May 18, 2022 · Background: A single cycle (two repeated treatments) with intrathecal autologous bone marrow-derived mesenchymal stem cells (BM-MSCs, 26-day interval) showed safety and …See details»
To Lead the Field of ALS Treatment Worldwide: Kadimastem …
Dec 7, 2016 · Israeli biotechnology company Kadimastem (TASE: KDST) announced today the signing of a memorandum of understanding with Korean company Corestem, for a broad …See details»
Efficacy and safety of Lenzumestrocel (Neuronata-R® inj
May 18, 2022 · The Clinical Research Organization (CRO) is designated for clinical operation (including periodic site monitoring), data management, safety reporting management, medical …See details»
(PDF) Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in ...
May 18, 2022 · Background: A single cycle (two repeated treatments) with intrathecal autologous bone marrow-derived mesenchymal stem cells (BM-MSCs, 26-day interval) showed safety and …See details»
CorEuStem • COST Action CA20140
CorEuStem consortium seeks to become a Pan European reference point for stakeholders in stem cell biology and associated technologies. The main objective of the CorEuStem is to …See details»